background image
Bio-Cybernetics is the application of cybernetics
(complex regulatory systems) to biological science.
While much of the pharma industry focuses
solely on "genomic outputs" of disease, the world
of bio-cybernetics is taking a much higher level
perspective on disease, looking at all the hierarchical
levels of control from the whole organism and its
environment, on down to genes and their complex
regulatory networks.
What we know about complex, multi-
factorial diseases, and the related regeneration /
reversion processes in nature, it would be quite
difficult to recapitulate any such dynamics with the
traditional pharma "single magic bullet" approach,
and more complex, "combinatorial" approaches will
be required to alter such systems and control them.
One area that our company, Bioquark Inc. has
been working on the past few years, is that of
"combinatorial biologics", focused on novel
combination biochemistries, and applying them for
the induction of complex regeneration and repair.
While the therapeutic targets for combinatorial
biologics we feel are quite broad in scope, Bioquark
is focusing to generating human clinical data in
discrete disease indications that represent areas of
substantial unmet medical need.
These include the formerly mentioned cancer
reversion opportunity, as well organ repair/
regeneration programs.
Whether we are talking about the 100,000 people
who die daily from age related ailments, or the
50,000 that die from acute traumas, it is well within
the intellectual capacity of humans to solve these
problems of disease, degeneration, and death.
But we must truly think "outside the box",
and not fall into the traps set by the traditional
pharmaceutical industry, its regulators, and the
century old model of drug development which has
truly run into a brick wall.
There is a reason that microbes, and plants,
and invertebrates, and amphibians, have survived
for many hundreds of millions of years on this
planet, and developed their own unique answers
to many of the problems that plague humanity.
Nature has shown us the way; we must now follow
her lead.
Ira Pastor - Chief Execu-
tive Officer Bioquark
Inc. - Over 30 years of ex-
perience across multiple
sectors of the pharmaceu-
tical industry including
pharmaceutical commer-
cialization, biotech drug
development, managed
care, distribution, OTC,
and retail; Served as VP,
Business Development for drug development compa-
ny Phytomedics Inc., raising $40 million of private eq-
uity, consummating over $50 million of licensing deals,
and bringing lead drug candidate from discovery stage
to Phase III development; Prior to that, employed by
SmithKline Beecham Pharmaceuticals working in sales,
marketing, and business strategy positions. Mr. Pastor
has also served as Vice President of Corporate Develop-
ment for the pharmacy benefit management company
Prescription Delivery Systems (acquired by Cigna Health
Insurance); MBA, Temple University; BS, Pharmacy, Rut-
gers University; He is also a Board Member of Regener-
Age SAPI de CV, ( a clinical
company focused on expedited translational therapeu-
tic applications of regenerative and rejuvenative health-
care interventions, the Reanima Project (http://www., member of the Executive Council of the
World Academy of Medical Science - WAMS (https://
of the World Economic Forum's Human Enhancement